Adherence to treatment guidelines for stage II or III colon cancer improved from 2001 to 2011 and resulted in improved survival outcomes.
Although the ASCO Value Framework is an important step to quantify the value of cancer therapies, a new study has found that it has essential limitations for its application in clinical practice for the treatment of chronic lymphocytic leukemia.
Two-year survivors with relapsed Hodgkin lymphoma or diffuse large B-cell lymphoma after transplant had an excess late mortality risk vs the general population.
Utilization of testing for mismatch repair deficiency was poor and underused in a large population of patients with colorectal cancer.
Levels of circulating tumor DNA predicted worse outcomes including relapse and survival in patients with resected stage II/III melanoma, according to the results of a study.
The addition of bevacizumab to lomustine for patients with progressive glioblastoma did not result in a significant improvement in overall survival.
Researchers are proposing the consideration of expanding criteria for liver debulking in pancreatic neuroendocrine tumors to include a threshold of greater than 70% debulking, intermediate grade tumors, positive margins, parenchyma-sparing resections, and extrahepatic metastases.
Even after 5 years of adjuvant endocrine therapy, women with ER-positive breast cancer experienced a steady rate of recurrences for as long as 20 years.
Treatment within 30 days of melanoma diagnosis was associated with improved outcomes; overall survival decreased in patients waiting longer than 90 days for surgery.
The majority of surveyed ovarian cancer patients required a 5-year survival benefit of 6% or less to justify an additional 50 miles of travel for cancer care.